# RAPT Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rapt-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.rapt.com/
- Total disclosed funding: $117M
- Latest round: Series C (Jun 20, 2019)
- Investors on record: 6

## About

RAPT Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics to treat inflammatory diseases and cancer, targeting key immune system drivers for improved patient outcomes.Founded in 2015 and headquartered in San Francisco, US, RAPT Therapeutics, Inc. specializes in the development of therapeutics for inflammatory diseases and cancer. The company has not undergone significant pivots in its business strategy since inception. RAPT was co-founded by Lowri Roberts and Nirav Panchmatia, with Brian Wong currently serving as CEO. The company has raised a total of USD 149.984 mn, with its most recent funding round being a PIPE in October 2019, which garnered USD 149.984 mn from various investors including TCG Crossover Management and The Column Group. Throughout its operation, RAPT has participated in 8 deals as part of its funding strategy.RAPT Therapeutics specializes in developing innovative therapeutics aimed at treating inflammatory diseases and cancer. Their core product offerings include RPT904, a long-acting anti-IgE antibody specifically designed to address food allergies, and Tivumecirnon (FLX475), a next-generation CCR4 antagonist targeting Th2-driven disorders such as atopic dermatitis and asthma. These therapies function by intelligently targeting key drivers of the immune system, thus transforming treatment paradigms for patients suffering from these conditions. RAPT's products are primarily intended for use in clinical settings, catering to patients with allergic diseases and various forms of cancer. The company focuses on markets in the United States and Europe, with an aim to extend its offerings into other international markets as its pipeline matures.In the fiscal year 2022, RAPT Therapeutics reported a revenue of USD 1.527 mn. The company generates revenue through partnerships with pharmaceutical companies and agreements with healthcare providers that support the advancement of their therapeutic products. Revenue streams may include milestone payments and royalties associated with the successful development and commercialization of products like RPT904 and Tivumecirnon.RAPT Therapeutics is strategically positioned for growth through the ongoing development of its product pipeline. The company aims to launch new products designed for the treatment of inflammatory diseases and cancer, with specific timelines yet to be announced. Additionally, RAPT plans to expand its market presence beyond the United States and Europe into other international regions as its offerings mature. The funding raised in the PIPE round in October 2019, which amounted to USD 149.984 mn, will be utilized to advance their clinical pipeline and support the commercialization of their products. In May 2022, they also raised USD 50 mn in a private placement to further bolster their financial position for these initiatives.

## Funding rounds

- Series C, Jun 20, 2019, $14M — Kleiner Perkins, T Rowe Price, The Column Group, Topspin Partners, GV, Bristol-Myers Squibb Company
- Series C, Dec 18, 2018, $23M — Kleiner Perkins, T Rowe Price, The Column Group, Topspin Partners, GV, Bristol-Myers Squibb Company
- Series C, Dec 15, 2017, $30M — Kleiner Perkins, The Column Group, Topspin Partners, GV, Bristol-Myers Squibb Company
- Series B, Apr 21, 2016, $50M — Kleiner Perkins, The Column Group, Topspin Partners, Bristol-Myers Squibb Company

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series C
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series B, Series C
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series B, Series C
- Bristol-Myers Squibb Company — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C